Good news frequently arrives | Haibu Pharmaceutical has been awarded the 2023 Star Council Member Unit by the National Federation of Industry and Commerce Pharmaceutical Industry Chamber.

On April 15, 2024, the 2nd Council Meeting of the 4th Session of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce and the Pharmaceutical Industry Development Forum in the Xihongqiao Business District were held in the Xihongqiao Business District with the theme "Gathering Strength for Pharmaceutical Innovation, Advancing Industry Towards New Directions." The council meeting is an annual routine meeting of the chamber, attended by over 400 representatives from various councils.

At the themed dinner, awards were presented for star-level vice presidents, star-level executive directors, star-level directors, and star-level members approved by the council. Haibu Pharmaceutical was awarded as a "Star-Level Director Unit of the National Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce 2023."

China National Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce(Abbreviated as: National Federation of Industry and Commerce Pharmaceutical Industry Chamber), approved by Document No. 200613 from the All-China Federation of Industry and Commerce, officially established on July 25, 2006, at the Great Hall of the People in Beijing. The chamber is a national industry organization initiated mainly by leading enterprises in domestic medicine and related fields, serving as a bridge and link between the party, government, and this industry.

Beijing Haibu Pharmaceutical Technology Co., Ltd. (abbreviated as "Haibu Pharmaceutical") was established in 2005 and is a high-tech enterprise with "chemical drug research and development" as its core capability. It has a research center in Beijing, an API and formulation pilot verification center, and a GMP industrial production base. It mainly engages in CRO services for APIs and formulations, MAH joint licensing, API-related declarations, and commercial supply of pharmaceutical intermediates.It has rich experience in R&D transfer production, registration declaration for various dosage forms such as chemical raw materials drugs, oral solids, liquid preparations, sterile injections, external preparations etc. The R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular diseases, digestive system diseases, respiratory system diseases.

Haibu Pharmaceutical has been awarded "Top 20 Chinese Pharmaceutical R&D Companies" for several consecutive years and recognized as a "Specialized & Innovative" enterprise in Beijing; a "National High-tech Enterprise"; a "Beijing Science & Technology Research Development Institution"; and a "Beijing Yizhuang Enterprise Innovation Center", among others.